Author: Ken Dropiewski

MIVI Neuroscience Promotes Bob Colloton to CEO and Appoints Robert Stern to Board of Directors

EDEN PRAIRIE, Minn., March 30, 2020 /PRNewswire/ — MIVI Neuroscience announced today that Bob Colloton has been promoted to the role of Chief Executive Officer effective March 30, 2020, following the resignation of MIVI’s current CEO, Jim McCollum. The Company also announced that Robert Stern, an experienced medical device executive and investor, has accepted the role of Vice […]

Medtronic Evolut TAVR System Demonstrates Excellent Outcomes in Study of Low-Risk Patients with Bicuspid Aortic Stenosis

ACC.20/WCC: Low Rates of Paravalvular Leak and High Survival Observed in Late-breaking Clinical Trial of Low-Risk Bicuspid Aortic Stenosis Patients DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced late-breaking clinical data from the Low Risk Bicuspid Study assessing the use of the […]

Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals’ Focus On COVID-19

IRVINE, Calif., March 28, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response […]

MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and Heart Failure with Preserved Ejection Fraction (HFpEF) MyoKardia to Host Webcast Conference Call at 4:30 p.m. EDT BRISBANE, Calif., March 30, 2020 […]

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure Apabetalone development program moving toward next study to enable a New Drug Application filing CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an […]

Medtronic Onyx ONE Clear Study of One-Month Dual-Antiplatelet Therapy in High Bleeding Risk Stent Patients Beats Performance Goal

First Study in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DES DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) […]

PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452 Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals® MALVERN, Pa. and SAN DIEGO, March 30, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a […]

Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis […]

Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)

ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69th Scientific Session Together with World Congress of […]

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication  Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation System DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED […]